FGFR1 and neoplasm: However, the potential systemic toxicity and limited drug absorption in vivo restrict the application of CQ in clinical tumor therapy.[40] To design an agent with a long administration period and low side effects to reverse AZD9291 resistance, we designed a multifunctional nanocarrier delivery system CP@NP‐cRGD that dual‐targeting FGFR1 pathway and autophagy.